Update on Transplacental Transfer of IgG Subclasses: Impact of Maternal and Fetal Factors

Toby Clements¹, Thomas F. Rice¹,², George Vamvakas³, Sara Barnett¹,², Megan Barnes¹, Beverly Donaldson², Christine E. Jones⁴, Beate Kampmann²,⁵,⁶ and Beth Holder¹,²*

¹Department of Metabolism, Digestion and Reproduction, Institute of Reproductive and Developmental Biology, Imperial College, London, United Kingdom
²Section of Paediatrics, Division of Infectious Diseases, Department of Medicine, Imperial College, London, United Kingdom
³Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, Kings College, London, United Kingdom
⁴Faculty of Medicine and Institute for Life Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
⁵The Vaccine Center, London School of Hygiene and Tropical Medicine, London, United Kingdom
⁶Vaccines and Immunity Theme, MRC Unit the Gambia at LSHTM, Banjul, Gambia

Transplacental antibody transfer from mother to fetus provides protection from infection in the first weeks of life, and the four different subclasses of IgG (IgG1, IgG2, IgG3, and IgG4) have diverse roles in protection against infection. In this study, we evaluated concentrations and transplacental transfer ratios of the IgG subclasses in a healthy UK-based cohort of mother-cord pairs, and investigated associations with maternal, obstetric, and fetal factors. In agreement with previous studies, we found a strong association between maternal and cord IgG for all subclasses. We report a transfer efficiency hierarchy of IgG1 > IgG3 > IgG4 = IgG2 in our study population, and our review of the literature demonstrates that there is no consensus in the hierarchy of subclass transfer, despite the commonly made statement that the order is IgG1 > IgG4 > IgG3 > IgG2. We report additional data regarding negative associations between elevated maternal IgG concentrations and maternal/cord transfer ratios, finding an effect on IgG1, IgG2, and IgG3 subclasses. Levels of IgG subclasses were the same between venous and arterial blood samples from the umbilical cord, but there was a significantly higher level of total IgG in arterial blood. We found no correlation between placental FcRn protein levels and IgG transfer in our cohort, suggesting that IgG is the main determinant of observed differences in transplacental transfer ratios at term. Neonatal IgG1 and IgG4 levels were increased with later gestation at delivery, independent of any increase in transplacental transfer, indicating that the benefit of later gestation is through accumulation of these subclasses in the fetus. Neonatal IgG2 levels and transfer ratios were reduced in rhesus-negative pregnancies, suggesting that administered anti-D antibodies may compete for transplacental transfer of this subclass. Maternal influenza vaccination resulted in elevated maternal and neonatal levels of IgG4, whereas maternal Tdap vaccination had no impact on neonatal levels of the subclasses, nor transfer. However, within Tdap vaccinated pregnancies, later gestation at...
INTRODUCTION

The neonatal period is a high-risk period for infectious diseases. Neonates are afforded some protection through passive immunity provided by maternal immunoglobulin (IgG) actively transferred across the placenta during pregnancy. This phenomenon has enabled maternal vaccination strategies aimed at boosting fetal levels of antigen-specific IgG for diseases associated with high neonatal mortality and morbidity. Maternal administration of tetanus and pertussis vaccines have both been highly successful at reducing rates of neonatal disease (1–4).

Transfer of IgG across the placental barrier is thought to involve interaction between IgG and the neonatal Fc receptor (FcRn) in the placental syncytiotrophoblast (5). FcRn is a heterodimer, consisting of an integral membrane glycoprotein which is structurally related to an MHC class I molecule and β2-microglobulin, and is capable of binding the IgG Fc region (6). The binding of FcRn to IgG only occurs at acidic pH 6 (7). For FcRn to bind IgG, IgG must therefore be taken up from the maternal circulation by the syncytiotrophoblast into endosomes which undergo acidification. The endosomes then fuse with the fetal side of the syncytiotrophoblast, leading to an increase in the pH, and the release of IgG into the stroma (8). It is not currently known how IgG crosses the stroma and the second placental barrier—the fetal endothelium—but FcRn may also be present in this endothelial layer (9). Other receptors or Fc-binding proteins found in the placenta could also be involved (6). More detail on the process of IgG transfer is available in our recently published review on FcRn-mediated transplacental antibody transfer (10).

IgG is divided into four subclasses, which cross the placenta with differential efficiency. The issue of transplacental transfer of the IgG subclasses is important, as they play diverse roles in immunity, and their production is differentially induced by distinct pathogens and vaccines [reviewed in (11)]. A number of papers and reviews state that the order of transplacental transfer is IgG1>IgG4>IgG3>IgG2, and that IgG2 transfer is “poor”. These usually reference one review (12) that has a graph illustrating data from a single study (13). We have identified 17 papers that have measured maternal and cord levels of the four IgG subclasses (13–29) (Figure 1). Calculating the mean from these papers produces transfer ratios of 1.36 for IgG1, 0.97 for IgG2, 1.12 for IgG3, and 1.12 for IgG4, although the high inter-study variation in both transfer ratios and the transfer hierarchy of the subclasses makes this average an oversimplification. Of the 17 papers, only seven (41%) report the transfer hierarchy of IgG1>IgG4>IgG3>IgG2. The reasons for these varying reports could be due to many differences in study populations including ethnicity, parity, BMI, placental weight, birth weight, gestation at birth, as well as maternal antigen exposure (through vaccination or infection) modifying antibody phenotype (including subclasses, antigen-specificity, and glycosylation).

Many previous studies of placental antibody transfer have been relatively small and often have not interrogated the effect of clinical variables other than gestation at delivery. Later gestation at delivery is associated with an increase in maternal to cord transfer ratios and in concentrations of antibody in cord blood (11, 30–32). However, several additional maternal and fetal factors have the potential to impact on placental antibody subclass transfer. This includes fetal sex, Rhesus status (and associated anti-D antibody administration), maternal vaccination, BMI, parity and ethnicity, among others.

It is important to understand the role of these factors when performing maternal vaccination studies in diverse patient populations. We performed IgG subclass analysis on a large number of maternal and cord blood samples, including an assessment of the impact of maternal and fetal factors on IgG subclass levels and transplacental transfer.

MATERIALS AND METHODS

Study Subjects and Sample Collection

Serum samples were obtained from 116 corresponding maternal and–cord blood pairs, as part of two maternal vaccination studies. These studies were approved by Research Ethics Committee (MatImms: REC 13/LO/1712. and COMET: REC 19/YH/0217) and written informed consent was obtained from all participants. Healthy women with singleton pregnancies with no known complications nor chronic or acute diseases were recruited. All pregnancies delivered at term (range 37+3 to 42+3). Detailed clinical data including BMI, parity, age, ethnicity, gestation at delivery, infant sex, birth weight, and maternal vaccination status were recorded. Individualized birthweight centiles (IBC) were calculated using GROW software (Perinatal Institute, version 8.0.4, gestation.net), which controls for maternal height, weight, ethnicity, and parity, and sex and gestation at birth. Serum samples were obtained from mothers near the time of birth (between 1 day before delivery and 3 days after delivery), and from the umbilical cord vein or artery within 1 h of delivery. Where possible, blood was collected separately from both the umbilical vein and the umbilical artery and this was recorded. Blood was collected into serum-separating tubes (BD) and left to clot for a minimum of 15 min before spinning at 1900G for 10 min. Serum was aliquoted and stored at −80°C.

Keywords: pregnancy, placenta, maternal vaccination, antibody, IgG, immunology, infection, neonatal
Clements et al. Transplacental Transfer of IgG Subclasses

FIGURE 1 | Overview of studies investigating maternal to fetal transfer ratios of IgG subclasses. We identified 17 papers that measured paired maternal and cord levels of all four IgG subclasses (13–22, 24–29). Studies had either employed radioimmunoassay, immunodiffusion, laser nephelometry or ELISA. The line graph represents the mean to fetal transfer ratio on a log(2) axis. Levels >1 (above the dotted line) indicates higher levels in cord blood compared to maternal blood. The dotted black line indicates the mean of the 16 studies. For Malek et al. (29) we only used the values from term pregnancies (37–41 weeks). For two studies, we performed ratio calculations based on reported maternal and cord concentrations (21, 29). For two other studies, values were calculated by reading from the published graphs (13, 15). For Costa-Carvalho et al. (13) this required us to read the ratios from the summary graph produced in the review by Palmerio et al. (12). In Hay et al. (28), the maternal levels of IgG1 were the lowest of all the other subclasses and maternal IgG2 was the highest (double the level of IgG1).

Immunoglobulin G (IgG) ELISAs
IgGs were measured using human Total IgG, IgG1, IgG2, IgG3, and IgG4 uncoated ELISA kits (Invitrogen) according to the manufacturer’s instructions. Absorbance was read at 450 nm using a VersaMax ELISA microplate reader.

Western Blotting
Washed placental villous tissue was lysed in cold RIPA buffer containing protease and phosphatase inhibitors (cOmplete\textsuperscript{TM} Protease Inhibitor Cocktail and PhosSTOP; Roche), in Lysing Prep D tubes (1.4 mm ceramic spheres), using a FastPrep-24 machine. Following centrifugation, protein supernatants were quantified by BCA assay (Pierce) using a VersaMax Microplate reader (Molecular Devices). Protein was prepared in reducing Laemmli SDS sample buffer (Alfa Aesar) and heated at 95°C for 5 min. Equal amounts of protein (25 µg) were separated on Bis-Tris gels and transferred onto PVDF membrane (iBLOT gel transfer stacks; Invitrogen). Membranes were stained for total protein using the MemCode\textsuperscript{TM} Reversible Protein Stain (Thermo Scientific) following the manufacturer’s instructions. This kit utilizes a high affinity protein stain which is compatible with subsequent western blotting. Following staining, membranes were imaged on the ImageQuant camera system (LAS 4000; GE Healthcare) to enable normalization of subsequent specific protein bands. This approach for normalization was employed due to the high variability of common protein loading controls in the placenta (33). After de-staining, membranes were blocked for 1h (5% dry milk, 1% BSA), and probed with 0.1µg/ml anti-FcRn antibody (SC B-8, Santa Cruz Biotechnology) overnight at 4°C. Bound antibody was detected through incubation with 0.125 µg/ml horseradish peroxidase (HRP)–conjugated goat anti-rabbit secondary antibody (Dako). Finally, membranes were developed using ECL Prime Western blotting detection reagent (Amersham) and Hyperfilm (Amersham). FcRn levels relative to total protein was determined by densitometry (ImageJ).

Statistical Analysis
Statistical analyses were performed in GraphPad Prism v8.0 and STATA v16. IgG concentrations were log transformed (natural Log) prior to analysis to achieve normality. Maternal to fetal transfer ratios were calculated by dividing the IgG concentration in cord blood, by the IgG concentration in paired maternal blood. These ratios were then log(2) transformed prior to analysis. Comparison of transfer ratios was performed using
Maternal and infant characteristics.

| Parameter                                      | Value          |
|------------------------------------------------|----------------|
| Maternal age, years (mean and range)           | 33 (20–45)     |
| Maternal height, cm (mean and range)           | 165 (135–181)  |
| Maternal weight, kg (mean and range)           | 67.1 (48.2–111) |
| BMI (mean and range)                           | 24.6 (17.9–38.9) |
| Blood group                                    |                |
| A (n and %)                                    | 43 (37%)       |
| B (n and %)                                    | 14 (12%)       |
| AB (n and %)                                   | 2 (1.7%)       |
| O (n and %)                                    | 57 (49%)       |
| Rhesus + (%)                                   | 87.9%          |
| Primiparous (%)                                | 56.62%         |
| Non-white ethnicity (%)                        | 41.4%          |
| Tdap vaccinated (%)                            | 61.2%          |
| Gestation at Tdap (weeks)                      | 30.8 (20–39)   |
| Flu vaccinated (%)                             | 50.0%          |
| Gestation at flu (weeks)                       | 24.8 (5–39)    |
| Vaginal delivery (%)                           | 44.0%          |
| Delivery with labor (%)                        | 53.4%          |
| Gestation at delivery (mean and range)         | 40.1 (37.4–42.3) |
| Male sex baby (%)                              | 51.7%          |
| Birth weight, kg (mean and range)              | 3.45 (2.32–4.45) |

Repeated Measures One Way ANOVA and Holm Sidak's multiple comparisons test. We looked at the effect of the following clinical parameters on antibody transfer: maternal age, maternal body mass index (BMI), rhesus status, ethnicity, parity, vaccination status (tetanus, diphtheria, acellular pertussis and inactivated poliomyelitis [Tdap/IPV] combination vaccination, or seasonal influenza vaccination), gestational age at vaccination, gestational age at delivery, infant sex, and individualized birth ratio (IBC). For ethnicity, we had subjects in 14 groups with small numbers in many; we therefore collapsed the groups into white (white British, white Irish and any other white background; 0) and non-white (black/black British, Asian/Asian British, mixed, and "other"; 1) to enable analysis. For parity, we combined those with parity 1–3 into one “parous” group (coded 1) and compared these to the primiparous group (no previous live births; 0).

Unadjusted and adjusted effects were estimated by simple and multiple linear regression models in Stata v16. Significance was assessed at the 5% level. All covariates that were significant at the 5% level entered the multiple regression models.

**RESULTS**

**Maternal and Cord Blood IgG Subclass Profiles and Transfer Ratios**

Clinical characteristics of the study subjects are shown in Table 1. As mothers were bled at varying times pre-/post-delivery, we checked that this did not impact on maternal IgG concentrations, which would bias the calculation of transfer ratios. Our study subjects were bled 1 day before delivery (n = 7), on the day of delivery (n = 78), within ½ day of delivery (n = 2), within 1 day (n = 20), 2 days (n = 5), or 3 days (n = 3).

There was no significant effect of timing of maternal bleed and maternal IgG concentrations (Supplemental Figure 1). Maternal and cord blood exhibited similar IgG subclass profiles, with relative abundance highest for IgG1, followed by IgG2, IgG3, then IgG4 in mothers, as well as their infants (Figure 2A). The maternal to fetal transfer ratio of IgG1 (1.538) was significantly higher than the other subclasses (Figure 2B). IgG3 also exhibited a small, but significantly higher transfer ratio (1.040) than both IgG2 (0.9326) and IgG4 (0.9330). When transfer ratios were normalized to total IgG levels in mothers, as a measure of relative transfer efficiency, a similar pattern of transfer was observed, although IgG3 was no longer significantly higher than IgG4 (Figure 2C). When transfer ratios were compared between pregnancies between 37+3 and 42+3 weeks gestation, similar relative transfer ratios were also observed, with significantly higher IgG1 transfer than the other subclasses at all gestations (Figure 2D). Paired comparison revealed significantly higher levels of total IgG and IgG1, and significantly lower levels of IgG2 and IgG4 in cord blood serum compared to matched maternal serum (Figure 2E). IgG3 was not significantly different between mothers and infants. The percentage of mother-cord pairs with transfer >1 was 83.6% for IgG1, 49.1% for IgG3, and 31.8% for both IgG2 and IgG4. Correlation plots of maternal and cord IgG levels show a positive correlation between maternal and cord antibody for total IgG and all IgG subclasses. Within the subclasses, the strongest correlation between maternal and cord levels is for IgG4, with the weakest correlation for IgG2 (Figure 2F). Additional descriptive statistics on the transfer of the subclasses is provided in Supplemental Table 1.

Maternal Antibody Concentrations Are Negatively Correlated With Maternal to Fetal Transfer Ratios of IgG Subclasses

As maternal levels of antigen-specific antibodies have been associated with reduced placental transfer ratios (11, 34), we investigated the association between maternal levels of antibody subclasses and transfer ratios (Figure 3). Maternal concentrations of total IgG, IgG1, and IgG3 were negatively associated with the transfer ratios of total IgG. Total IgG, IgG1, IgG2, and IgG3 were negatively associated with transfer of IgG1–IgG3. Maternal concentrations of IgG4 were only negatively associated with the transfer ratios of IgG1.

Maternal to Fetal Transfer Ratios Are Largely Unaffected by Sampling of the Umbilical Artery or Umbilical Vein

As the umbilical vein represents oxygenated blood flowing from the placenta, and the umbilical arteries represent deoxygenated blood flowing from the fetus (Figure 4A), we investigated whether any differences could be observed in blood sampled from these two vessels. Although total IgG levels were significantly higher in arterial blood, this difference was not borne out in the analysis of the IgG subclasses (Figure 4B). Both maternal: umbilical vein IgG levels, and maternal: umbilical artery IgG levels were positively correlated (Figure 4C).
FIGURE 2 | Maternal and cord blood IgG subclass profiles and transfer ratios. (A) IgG1–4 concentrations (µg/ml) in maternal (M) and cord (C) blood on a log(2) axis. (B) Maternal to fetal transfer ratios of IgG1–4 represented on log(2) scale. Values > 1 indicate higher levels in cord blood, indicated by dashed line. Analysis performed on log(2) transformed transfer ratios, using Repeated Measures One Way ANOVA and Holm Sidak’s multiple comparisons test. (C) Maternal to fetal transfer ratios of IgG1–4 normalized to levels of total IgG in maternal blood as an indicator of transfer efficiency. Analysis by Repeated Measures One Way ANOVA and Holm Sidak’s (Continued)
Correlation Between Placental FcRn Expression and Transfer of IgG Subclasses

Transplacental antibody transfer across the syncytiotrophoblast layer of the placenta is mediated through interaction with the neonatal Fc receptor [FcRn; reviewed in (10)]. To investigate whether inter-individual differences in IgG subclass transfer are due to differences in FcRn levels in the placenta, western blotting of paired placental samples was performed (Figure 5). With the set of paired samples available ($n = 20$), no association was detected between placental FcRn
levels and the transfer ratio of total IgG nor subclasses 1-4 (Figure 5C).

Investigation of Clinical Variables Associated With Levels and Transfer of IgG: Unadjusted Effects

Unadjusted analyses were performed to explore relationships between clinical variables and maternal and cord IgG concentrations, as well as the maternal to fetal transfer of IgG subclasses (Tables 2–4). Increased maternal age was associated with lower total IgG in mothers (p = 0.042; Table 2), but had no effect on cord levels (Table 3) nor transfer (Table 4). Non-white women had higher levels of total IgG, IgG2, and IgG3 (p = 0.034, 0.019, and 0.024; Table 2). There was no corresponding increase in infant IgG levels, and the calculated transfer ratios of IgG3 in these pregnancies was significantly lower (p = 0.004; Table 4). Parous women had higher levels of total IgG (p = 0.004) and IgG1 (p = 0.034) compared to primiparous. The transfer ratios of total, IgG1 and IgG3 in these pregnancies was significantly lower (p = 0.023, 0.001, and 0.001; Table 4), resulting in no corresponding increase in infant IgG levels (Table 3). Although maternal rhesus status had no effect on maternal IgG levels, rhesus negative pregnancies were associated with lower transfer of IgG2 (p = 0.048) and a corresponding lower level of IgG2 in cord blood (p = 0.047) compared to rhesus positive pregnancies.

Later gestation at delivery was associated with lower maternal levels of total IgG (p = 0.018) and higher IgG4 (p = 0.003). Transfer ratios were higher with later gestation at delivery for total IgG, IgG1, and IgG3 (p = 0.002, 0.04, and 0.015; Table 4). The outcome of later gestation at delivery was higher neonatal levels of IgG1 and IgG4 (p = 0.013, 0.001; Table 3). Neonates with higher birth centiles had lower levels of total IgG and IgG2 (p = 0.004, 0.042; Table 3). Pregnancies with higher centile infants also
had lower maternal to fetal transfer of IgG1 (p = 0.032) and IgG4 (p = 0.015; Table 4). Maternal BMI and sex of the neonate had no impact on any variables.

Impact of Maternal Tdap/IPV and Influenza Vaccination on IgG Subclass Levels and Transfer

Sixty-one percent of our cohort received Tdap vaccination in pregnancy, and 50% received seasonal influenza vaccine (Table 1). Tdap vaccination status had no effect on maternal or cord IgG concentrations nor IgG transfer. Influenza vaccination was associated with higher IgG4 in mothers (p = 0.038; Table 2) and neonates (p = 0.019; Table 3), with no impact on transfer ratios (Table 4).

The gestation at Tdap vaccination was positively correlated with maternal to fetal transfer for IgG1 (p = 0.001), IgG2 (p = 0.007), IgG3 (p = 0.006), and IgG4 (p = 0.004; Table 4, Figure 6A). There was no association between timing of Tdap and maternal nor cord IgG concentrations (Tables 2, 3, Figure 6B). Later gestation at influenza vaccination was associated with higher levels of total IgG in mums (p = 0.012; Table 2), but had no effect on neonatal levels nor transfer. The transfer ratio of IgG3 was lower with later gestation at vaccination (p = 0.013; Table 4).

Adjusted Effects Associated With Transfer of IgG Subclasses

We next performed multiple regression analyses that included the variables that were found to be significant at the 5% level in our unadjusted analyses (Tables 2–4).

In the adjusted analysis, levels of total IgG in maternal serum was associated with both parity and maternal age, but not with gestation at delivery nor ethnicity (Table 5). Parous women had higher levels of total IgG than primiparous women (p = 0.015), and older women had lower levels of total IgG (p = 0.018), after adjusting for gestation at delivery and for ethnicity. Parous pregnancies had lower transfer ratios of IgG1 (p = 0.006), after adjusting for gestation at delivery and birth centiles. Later gestation at delivery was associated with higher transfer ratios of total IgG and IgG3 (p = 0.008). IgG3 transfer was also significantly lower in pregnancies of non-white women (p = 0.012).

We investigated the association between the clinical variables in these models. Parity was associated with gestation at birth (p = 0.019), with the individualized birth weight centile (IBC; p =
### TABLE 2 | Unadjusted effects of clinical parameters on maternal antibody concentrations using simple linear regression based on $n = 106$ for total IgG and $n = 116$ for IgG subclasses.

| Variable                     | Antibody | Coefficient | Standard error | $p$-value | 95% CI     |
|------------------------------|----------|-------------|----------------|-----------|------------|
| Maternal age (years)         | Total    | −0.014      | 0.007          | 0.042     | −0.027, −0.001 |
|                              | IgG1     | −0.013      | 0.012          | 0.275     | −0.037, 0.011 |
|                              | IgG2     | −0.007      | 0.011          | 0.546     | −0.029, 0.015 |
|                              | IgG3     | 0.012       | 0.015          | 0.401     | −0.017, 0.041 |
|                              | IgG4     | −0.020      | 0.029          | 0.484     | −0.077, 0.037 |
| Maternal BMI                 | Total    | 0.008       | 0.008          | 0.305     | −0.007, 0.023 |
|                              | IgG1     | −0.004      | 0.014          | 0.759     | −0.032, 0.023 |
|                              | IgG2     | −0.003      | 0.013          | 0.815     | −0.028, 0.022 |
|                              | IgG3     | 0.015       | 0.017          | 0.368     | −0.018, 0.048 |
|                              | IgG4     | −0.007      | 0.033          | 0.826     | −0.073, 0.058 |
| Maternal ethnicity           | Total    | 0.139       | 0.065          | 0.034     | 0.011, 0.268 |
| (white = 0; non-white = 1)   | IgG1     | 0.170       | 0.114          | 0.141     | −0.057, 0.396 |
|                              | IgG2     | 0.247       | 0.104          | 0.019     | 0.041, 0.452 |
|                              | IgG3     | 0.314       | 0.138          | 0.024     | 0.042, 0.587 |
|                              | IgG4     | −0.065      | 0.277          | 0.815     | −0.614, 0.484 |
| Parity                       | Total    | 0.188       | 0.063          | 0.004     | 0.062, 0.314 |
| (primiparous = 0; parous = 1)| IgG1     | 0.243       | 0.113          | 0.034     | 0.019, 0.467 |
|                              | IgG2     | 0.187       | 0.105          | 0.077     | −0.020, 0.394 |
|                              | IgG3     | 0.263       | 0.139          | 0.061     | −0.012, 0.537 |
|                              | IgG4     | 0.158       | 0.277          | 0.570     | −0.390, 0.706 |
| Rhesus status (negative = 0; positive = 1) | Total | 0.078       | 0.111          | 0.486     | −0.142, 0.298 |
|                              | IgG1     | 0.112       | 0.174          | 0.523     | −0.233, 0.457 |
|                              | IgG2     | 0.072       | 0.161          | 0.655     | −0.246, 0.390 |
|                              | IgG3     | 0.204       | 0.212          | 0.339     | −0.216, 0.624 |
|                              | IgG4     | −0.441      | 0.418          | 0.292     | −1.267, 0.385 |
| Gestation at delivery (weeks)| Total    | −0.068      | 0.028          | 0.018     | −0.124, −0.012 |
|                              | IgG1     | 0.026       | 0.051          | 0.605     | −0.074, 0.127 |
|                              | IgG2     | −0.013      | 0.047          | 0.779     | −0.106, 0.079 |
|                              | IgG3     | −0.010      | 0.062          | 0.874     | −0.132, 0.113 |
|                              | IgG4     | 0.361       | 0.117          | 0.003     | 0.129, 0.593 |
| Sex of baby (male = 0; female = 1) | Total | −0.018      | 0.065          | 0.780     | −0.148, 0.111 |
|                              | IgG1     | 0.033       | 0.114          | 0.775     | −0.193, 0.258 |
|                              | IgG2     | 0.083       | 0.104          | 0.373     | −0.113, 0.300 |
|                              | IgG3     | −0.138      | 0.138          | 0.321     | −0.411, 0.136 |
|                              | IgG4     | 0.248       | 0.272          | 0.365     | −0.291, 0.787 |
| Individualized birth ratio (IBC) | Total | −0.002      | 0.001          | 0.075     | −0.004, 0.001 |
|                              | IgG1     | 0.0001      | 0.002          | 0.942     | −0.004, 0.004 |
|                              | IgG2     | −0.002      | 0.002          | 0.355     | −0.005, 0.002 |
|                              | IgG3     | 0.003       | 0.002          | 0.263     | −0.002, 0.008 |
|                              | IgG4     | −0.003      | 0.005          | 0.544     | −0.013, 0.007 |
| Tdap maternal vaccination status (non-vacc = 0; vacc = 1) | Total | 0.003       | 0.067          | 0.966     | −0.126, 0.135 |
|                              | IgG1     | 0.180       | 0.115          | 0.121     | −0.049, 0.049 |
|                              | IgG2     | 0.035       | 0.107          | 0.742     | −0.177, 0.248 |
|                              | IgG3     | 0.146       | 0.142          | 0.305     | −0.135, 0.426 |
|                              | IgG4     | −0.031      | 0.280          | 0.911     | −0.586, 0.523 |
| Tdap maternal vaccination timing (gestational weeks) | Total | −0.008      | 0.014          | 0.593     | −0.036, 0.021 |
|                              | IgG1     | −0.022      | 0.023          | 0.328     | −0.068, 0.023 |
|                              | IgG2     | −0.025      | 0.020          | 0.226     | −0.066, 0.016 |
|                              | IgG3     | 0.003       | 0.027          | 0.919     | −0.052, 0.058 |
|                              | IgG4     | 0.012       | 0.052          | 0.823     | −0.093, 0.116 |

(Continued)


Figure 2F and negatively associated with the maternal to fetal transfer ratios (Figure 3). As has been previously well established, we found higher levels of total IgG and IgG1 in cord blood compared to maternal blood, reflected in a mean transfer ratio of 1.5 for IgG1. The transfer ratio of the other subclasses was near to 1. In our study population the transfer efficiency of the subclasses was IgG1 > IgG3 > IgG4 = IgG2 (Figure 2B). The transfer ratio of IgG1 was significantly higher than the ratios of the other subclasses at all gestations studied (between 37 weeks and 42 weeks; Figure 2D), suggesting that delivery post-dates does not affect the relative maternal/cord ratios of IgG subclasses.

Maternal antibodies may compete for transplacental transfer through their competition for placental FcRn, which binds IgG in a 2:1 stoichiometry (35). Several studies have shown that maternal total and antigen-specific IgG concentrations are inversely correlated with maternal/cord ratios of total and antigen-specific IgG (11, 17, 34, 36), supporting the concept that antibody does not passively diffuse across the placenta to reach equilibrium between maternal and fetal circulations, but requires interaction with FcRn (and other potential Fc receptors) for its transfer. There have been fewer studies of the association between maternal levels of the IgG subclasses and transplacental transfer. One study of placental malaria and maternal hypergammaglobulinemia found an association between maternal IgG levels >15g/L IgG and reduced transfer of IgG1 and IgG2, with no effect on IgG3 and IgG4, compared to maternal levels <15g/L (17). Our analysis performing correlations on continuous data found a negative correlation between maternal total IgG levels and the transfer ratios of total IgG, IgG1, IgG2, and IgG3 subclasses in healthy pregnancy. We also found that maternal concentrations of IgG1, IgG2, and IgG3 were negatively correlated with transfer ratios of total IgG and IgG1–3. This suggests that the higher abundance IgG1, IgG2, and IgG3 may all compete with their respective, and other subclasses, for transfer across the placenta. Importantly, it must be noted that within maternal blood, the concentrations of IgG2, IgG3, and IgG4 are all correlated with IgG1. Thus, the effects observed cannot be necessarily be attributed specifically to a certain subclass, but could be driven by IgG1, which is highest in abundance and transferred with the highest efficiency. With that said, increased maternal IgG4 levels had limited correlation with IgG transfer, and transfer of IgG4 was not correlated with maternal levels of any antibody, even though maternal IgG4 levels are positively correlated with maternal IgG1. Furthermore, IgG4 had the strongest correlation between maternal and cord IgG concentrations, which altogether suggests that the transfer of this subclass is least affected by changes in amounts of antibody in the mother. The clinical significance of this phenomenon on passive immunity in the neonate is likely to lie in the potential impact on the transfer of antibodies against specific pathogens, which should be explored.

It is important to note that this commonly utilized approach of employing maternal/cord IgG ratios as an indicator of transplacental transfer efficiency has its limitations. The relative abundance between paired maternal-cord samples is not necessarily a true reflection of transfer efficiency as this could be biased by maternal concentrations, as well as the levels of IgG recycling in fetal and maternal circulations. To partly address this, we have shown that normalization of transfer ratios to total IgG levels in maternal blood show the same pattern of differential

---

**DISCUSSION**

We have performed a comprehensive analysis of maternal and cord levels of the IgG subclasses and transplacental transfer in a UK pregnancy cohort, and investigated their association with maternal and fetal factors.

As previously observed, maternal concentrations of total IgG and IgG subclasses were positively associated with umbilical cord concentrations (Figure 2F) and negatively associated with the maternal to fetal transfer ratios (Figure 3). As has been previously well established, we found higher levels of total IgG and IgG1 in cord blood compared to maternal blood, reflected in a mean transfer ratio of 1.5 for IgG1. The transfer ratio of the other subclasses was near to 1. In our study population the transfer efficiency of the subclasses was IgG1 > IgG3 > IgG4 = IgG2 (Figure 2B). The transfer ratio of IgG1 was significantly higher than the ratios of the other subclasses at all gestations studied (between 37 weeks and 42 weeks; Figure 2D), suggesting that delivery post-dates does not affect the relative maternal/cord ratios of IgG subclasses.

Maternal antibodies may compete for transplacental transfer through their competition for placental FcRn, which binds IgG in a 2:1 stoichiometry (35). Several studies have shown that maternal total and antigen-specific IgG concentrations are inversely correlated with maternal/cord ratios of total and antigen-specific IgG (11, 17, 34, 36), supporting the concept that antibody does not passively diffuse across the placenta to reach equilibrium between maternal and fetal circulations, but requires interaction with FcRn (and other potential Fc receptors) for its transfer. There have been fewer studies of the association between maternal levels of the IgG subclasses and transplacental transfer. One study of placental malaria and maternal hypergammaglobulinemia found an association between maternal IgG levels >15g/L IgG and reduced transfer of IgG1 and IgG2, with no effect on IgG3 and IgG4, compared to maternal levels <15g/L (17). Our analysis performing correlations on continuous data found a negative correlation between maternal total IgG levels and the transfer ratios of total IgG, IgG1, IgG2, and IgG3 subclasses in healthy pregnancy. We also found that maternal concentrations of IgG1, IgG2, and IgG3 were negatively correlated with transfer ratios of total IgG and IgG1–3. This suggests that the higher abundance IgG1, IgG2, and IgG3 may all compete with their respective, and other subclasses, for transfer across the placenta. Importantly, it must be noted that within maternal blood, the concentrations of IgG2, IgG3, and IgG4 are all correlated with IgG1. Thus, the effects observed cannot be necessarily be attributed specifically to a certain subclass, but could be driven by IgG1, which is highest in abundance and transferred with the highest efficiency. With that said, increased maternal IgG4 levels had limited correlation with IgG transfer, and transfer of IgG4 was not correlated with maternal levels of any antibody, even though maternal IgG4 levels are positively correlated with maternal IgG1. Furthermore, IgG4 had the strongest correlation between maternal and cord IgG concentrations, which altogether suggests that the transfer of this subclass is least affected by changes in amounts of antibody in the mother. The clinical significance of this phenomenon on passive immunity in the neonate is likely to lie in the potential impact on the transfer of antibodies against specific pathogens, which should be explored.

It is important to note that this commonly utilized approach of employing maternal/cord IgG ratios as an indicator of transplacental transfer efficiency has its limitations. The relative abundance between paired maternal-cord samples is not necessarily a true reflection of transfer efficiency as this could be biased by maternal concentrations, as well as the levels of IgG recycling in fetal and maternal circulations. To partly address this, we have shown that normalization of transfer ratios to total IgG levels in maternal blood show the same pattern of differential

---

**TABLE 2 | Continued**

| Variable | Antibody | Coefficient | Standard error | p-value | 95% CI |
|----------|----------|-------------|----------------|---------|-------|
| Flu maternal vaccination status (non-vacc = 0; vacc = 1) | Total | 0.032 | 0.065 | 0.621 | −0.097, 0.161 |
| | IgG1 | 0.183 | 0.112 | 0.107 | −0.040, 0.405 |
| | IgG2 | −0.038 | 0.105 | 0.718 | −0.245, 0.169 |
| | IgG3 | 0.080 | 0.138 | 0.519 | −0.185, 0.364 |
| | IgG4 | 0.563 | 0.288 | 0.038 | 0.033, 1.094 |
| Flu maternal vaccination timing (gestational weeks) | Total | 0.015 | 0.006 | 0.012 | 0.003, 0.026 |
| | IgG1 | 0.004 | 0.010 | 0.668 | −0.016, 0.025 |
| | IgG2 | 0.017 | 0.009 | 0.057 | −0.001, 0.035 |
| | IgG3 | 0.006 | 0.013 | 0.650 | −0.020, 0.032 |
| | IgG4 | −0.001 | 0.023 | 0.982 | −0.046, 0.045 |

**Bold values indicate p value < 0.05.**
### TABLE 3 | Unadjusted effects of clinical parameters on umbilical cord antibody concentrations using simple linear regression based on n = 106 for total IgG and n = 116 for IgG subclasses.

| Antibody | Coefficient | Standard error | p-value | 95% CI    |
|----------|-------------|----------------|---------|-----------|
| Maternal age (years) |  |  |  |  |
| Total | −0.006 | 0.005 | 0.234 | −0.016, 0.004 |
| IgG1 | −0.014 | 0.010 | 0.162 | −0.034, 0.006 |
| IgG2 | −0.006 | 0.012 | 0.622 | −0.029, 0.017 |
| IgG3 | 0.013 | 0.013 | 0.312 | −0.013, 0.040 |
| IgG4 | −0.018 | 0.032 | 0.577 | −0.081, 0.045 |
| Maternal BMI Total | 0.004 | 0.006 | 0.443 | −0.007, 0.015 |
| IgG1 | −0.009 | 0.011 | 0.445 | −0.031, 0.014 |
| IgG2 | −0.002 | 0.013 | 0.876 | −0.028, 0.024 |
| IgG3 | 0.006 | 0.015 | 0.685 | −0.024, 0.037 |
| IgG4 | −0.021 | 0.036 | 0.560 | −0.093, 0.051 |
| Maternal ethnicity (white = 0; non-white = 1) |  |  |  |  |
| Total | 0.054 | 0.047 | 0.255 | −0.040, 0.148 |
| IgG1 | 0.025 | 0.096 | 0.792 | −0.165, 0.215 |
| IgG2 | 0.163 | 0.111 | 0.142 | −0.055, 0.382 |
| IgG3 | 0.152 | 0.129 | 0.240 | −0.103, 0.408 |
| IgG4 | 0.008 | 0.304 | 0.978 | −0.059, 0.611 |
| Parity (primiparous = 0; parous = 1) |  |  |  |  |
| Total | 0.056 | 0.047 | 0.236 | −0.037, 0.149 |
| IgG1 | −0.018 | 0.096 | 0.855 | −0.208, 0.172 |
| IgG2 | 0.031 | 0.112 | 0.784 | −0.190, 0.252 |
| IgG3 | 0.080 | 0.130 | 0.539 | −0.177, 0.337 |
| IgG4 | −0.049 | 0.304 | 0.873 | −0.651, 0.553 |
| Rhesus status (negative = 0; positive = 1) |  |  |  |  |
| Total | 0.076 | 0.079 | 0.338 | −0.081, 0.234 |
| IgG1 | 0.177 | 0.144 | 0.223 | −0.109, 0.462 |
| IgG2 | 0.334 | 0.166 | 0.047 | 0.005, 0.662 |
| IgG3 | 0.275 | 0.194 | 0.161 | −0.111, 0.660 |
| IgG4 | −0.140 | 0.459 | 0.762 | −1.049, 0.770 |
| Gestation at delivery (weeks) Total | 0.018 | 0.021 | 0.375 | −0.023, 0.060 |
| IgG1 | 0.104 | 0.041 | 0.013 | 0.022, 0.185 |
| IgG2 | 0.059 | 0.049 | 0.229 | −0.038, 0.156 |
| IgG3 | 0.061 | 0.057 | 0.283 | −0.051, 0.174 |
| IgG4 | 0.429 | 0.128 | 0.001 | 0.176, 0.681 |
| Sex of baby (male = 0; female = 1) |  |  |  |  |
| Total | 0.034 | 0.047 | 0.469 | −0.059, 0.127 |
| IgG1 | 0.000 | 0.096 | 0.999 | −0.187, 0.187 |
| IgG2 | 0.022 | 0.110 | 0.838 | −0.195, 0.240 |
| IgG3 | −0.137 | 0.127 | 0.283 | −0.390, 0.115 |
| IgG4 | 0.179 | 0.299 | 0.550 | −0.413, 0.772 |
| Individualized birth ratio (IBC) Total | −0.002 | 0.001 | 0.004 | −0.004, −0.001 |
| IgG1 | −0.003 | 0.002 | 0.099 | −0.006, 0.001 |
| IgG2 | −0.004 | 0.002 | 0.043 | −0.006, −0.000 |
| IgG3 | 0.002 | 0.002 | 0.294 | −0.002, 0.007 |
| IgG4 | −0.008 | 0.005 | 0.139 | −0.018, 0.003 |
| Tdap maternal vaccination status (non-vacc = 0; vacc = 1) Total | 0.047 | 0.048 | 0.332 | −0.048, 0.141 |
| IgG1 | 0.076 | 0.097 | 0.433 | −0.116, 0.268 |
| IgG2 | −0.055 | 0.113 | 0.626 | −0.278, 0.168 |
| IgG3 | 0.165 | 0.130 | 0.207 | −0.093, 0.423 |
| IgG4 | −0.140 | 0.307 | 0.649 | −0.748, 0.468 |
| Tdap maternal vaccination timing (gestational weeks) Total | 0.016 | 0.009 | 0.079 | −0.002, 0.034 |
| IgG1 | 0.031 | 0.019 | 0.115 | −0.008, 0.069 |
| IgG2 | 0.024 | 0.023 | 0.296 | −0.022, 0.070 |
| IgG3 | 0.033 | 0.025 | 0.199 | −0.018, 0.083 |
| IgG4 | 0.090 | 0.059 | 0.133 | −0.028, 0.208 |

(Continued)
transfer of the IgG subclasses (Figure 2C). We also show a similar pattern of relative transfer ratios between 37 and 42 weeks gestation. In vitro competition assays in human trophoblast or non-human primate in vivo experiments with spike-in of IgG subclasses are required to fully understand the competition for transplacental transfer between the IgG subclasses. Nevertheless, our data appears to support the current consensus that although higher IgG levels in the mother will result in higher IgG levels in the offspring, the relative transfer efficiency across the placenta can be reduced when maternal concentrations are elevated.

Given the limited capability for IgG production in the fetus, the majority of antibody in the fetal circulation is maternal in origin. We hypothesized that IgG levels in the umbilical arteries (bringing deoxygenated blood from the fetus) would be higher than levels in the umbilical vein (bringing freshly oxygenated blood from the placenta). In contrast however, we found no significant difference in the abundance of the IgG subclasses, and only a slightly but significantly higher level of total IgG in the umbilical artery. This was a surprising finding and could suggest that there is greater hemolysis in venous blood compared to arterial blood, or it could reflect efficient total antibody recycling in the fetal circulation leading to higher levels in blood coming from the fetus. No other study has investigated this to our knowledge. It could be of interest to investigate FcRn levels in the venous and arterial endothelium of the umbilical cord and in the placental vasculature, as this is involved in antibody recycling, thereby increasing half-life. It would also be of interest to determine whether there are differences in the levels of antigen-specific antibodies between venous and arterial umbilical blood. This finding suggests that it is important that maternal vaccination studies sample from the same umbilical/placental vessels in case there are some as yet unidentified differences between these biofluids.

For a subset of samples, we performed measurement of FcRn in matched placenta. We found no significant correlation between placental levels of FcRn and the transfer rates of total IgG nor any of the antibody subclasses. One previous study has correlated placental FcRn with transfer ratios, and concluded that there was a positive association (37). However, this study measured “the percentage of the total area in the placental tissue with FcRn expression.” As the placental structure changes with gestation, including the proportions of the different cell types, measuring the percentage of tissue with FcRn content could be interpreted as just a measurement of syncytiotrophoblast surface area, rather than the concentration of FcRn within this tissue. Our measurement of FcRn by western blotting also has its limitations, given that it is measured in a mixed homogenate of placental tissue. Importantly however, we only looked at term placentas, which reduces the effect of gestational changes in placental structure. Our data suggests that inter-individual differences in transplacental transfer are mainly driven by differences in IgG, however this question warrants further investigation in a larger cohort, as well as investigation of other Fc receptors.

Finally, we explored the potential clinical variables that may impact on maternal and cord levels, and transfer ratios of total IgG and the IgG subclasses. Only a few variables impacted on the concentration of IgG in neonatal blood. Babies born at later gestation had significantly higher levels of IgG1 and IgG4. For IgG4 this appears to have been facilitated by significantly higher levels of IgG4 in the mothers, that was then passed to the fetus, rather than an increase in the rate of transplacental transfer (which was unchanged). For IgG1, maternal levels were no different with later gestation, and following adjustment for other associated variables, gestation was also not associated with the IgG1 transfer ratio. This suggests that the higher IgG1 at later gestation may reflect an accumulation of IgG1 in the fetal circulation over time, rather than an increased ability of the placenta to transfer IgG in the last weeks of term pregnancy. Several other studies have found a positive association between total IgG and antigen-specific IgG and gestation (11, 30–32). The main difference is that we studied healthy term (>37 weeks) pregnancies, unlike other studies which looked at the effect of prematurity. Our study shows that even at term, every additional weeks’ delay in delivery increases neonatal levels of IgG1 and IgG4.

Birth centiles were negatively correlated with neonatal levels of total IgG and of IgG2. This does not appear to be related to a change in maternal levels, nor lower transfer ratio of these
TABLE 4 | Unadjusted effects of clinical parameters on log(2) maternal to fetal IgG transfer ratios using simple linear regression based on n = 106 for total IgG and n = 116 for IgG subclasses.

| Variable                               | Antibody | Coefficient | Standard error | p-value  | 95% CI        |
|----------------------------------------|----------|-------------|----------------|----------|---------------|
| Maternal age                           | Total    | 0.012       | 0.009          | 0.189    | −0.006, 0.029 |
| (years)                                | IgG1     | −0.001      | 0.012          | 0.920    | −0.025, 0.022 |
|                                        | IgG2     | 0.001       | 0.013          | 0.918    | −0.025, 0.028 |
|                                        | IgG3     | 0.002       | 0.009          | 0.825    | −0.015, 0.019 |
|                                        | IgG4     | 0.004       | 0.018          | 0.835    | −0.031, 0.039 |
| Maternal BMI                           | Total    | 0.005       | 0.010          | 0.593    | −0.025, 0.014 |
|                                        | IgG1     | −0.007      | 0.013          | 0.628    | −0.033, 0.020 |
|                                        | IgG2     | 0.001       | 0.015          | 0.932    | −0.029, 0.031 |
|                                        | IgG3     | −0.013      | 0.010          | 0.200    | −0.032, 0.007 |
|                                        | IgG4     | −0.020      | 0.020          | 0.319    | −0.060, 0.020 |
| Maternal ethnicity                      | Total    | −0.123      | 0.084          | 0.147    | −0.289, 0.044 |
| (white = 0; non-white = 1)             | IgG1     | −0.208      | 0.111          | 0.064    | −0.429, 0.012 |
|                                        | IgG2     | −0.120      | 0.127          | 0.344    | −0.371, 0.131 |
|                                        | IgG3     | −0.234      | 0.081          | 0.004    | −0.394, −0.074|
|                                        | IgG4     | 0.106       | 0.168          | 0.530    | −0.228, 0.440 |
| Parity                                 | Total    | −0.190      | 0.083          | 0.023    | −0.354, −0.026|
| (primiparous = 0; parous = 1)          | IgG1     | −0.376      | 0.107          | 0.001    | −0.588, −0.163|
|                                        | IgG2     | −0.226      | 0.125          | 0.074    | −0.474, 0.022 |
|                                        | IgG3     | −0.284      | 0.080          | 0.001    | −0.422, −0.105|
|                                        | IgG4     | −0.298      | 0.166          | 0.076    | −0.627, 0.032 |
| Rhesus status                          | Total    | −0.002      | 0.143          | 0.990    | −0.285, 0.281 |
| (negative = 0; positive = 1)           | IgG1     | 0.094       | 0.171          | 0.583    | −0.244, 0.432 |
|                                        | IgG2     | 0.378       | 0.189          | 0.048    | 0.003, 0.752  |
|                                        | IgG3     | 0.103       | 0.126          | 0.417    | −0.147, 0.352 |
|                                        | IgG4     | 0.435       | 0.252          | 0.087    | −0.064, 0.934 |
| Gestation at delivery                  | Total    | 0.110       | 0.035          | 0.002    | 0.041, 0.179  |
| (weeks)                                | IgG1     | 0.099       | 0.048          | 0.040    | 0.005, 0.193  |
|                                        | IgG2     | 0.104       | 0.054          | 0.055    | −0.002, 0.210 |
|                                        | IgG3     | 0.086       | 0.035          | 0.015    | 0.017, 0.155  |
|                                        | IgG4     | 0.084       | 0.072          | 0.245    | −0.058, 0.226 |
| Sex of baby                            | Total    | 0.075       | 0.083          | 0.368    | −0.090, 0.241 |
| (male = 0; female = 1)                 | IgG1     | −0.047      | 0.111          | 0.675    | −0.267, 0.174 |
|                                        | IgG2     | −0.102      | 0.125          | 0.415    | −0.350, 0.145 |
|                                        | IgG3     | 0.001       | 0.082          | 0.994    | −0.162, 0.164 |
|                                        | IgG4     | −0.099      | 0.166          | 0.554    | −0.428, 0.230 |
| Individualized birth ratio              | Total    | −0.000      | 0.001          | 0.764    | −0.003, 0.003 |
| (IBC)                                  | IgG1     | −0.004      | 0.002          | 0.332    | −0.006, 0.000 |
|                                        | IgG2     | −0.003      | 0.002          | 0.151    | −0.008, 0.001 |
|                                        | IgG3     | −0.001      | 0.001          | 0.716    | −0.003, 0.002 |
|                                        | IgG4     | −0.007      | 0.003          | 0.015    | −0.013, −0.001|
| Tdap maternal vaccination status        | Total    | 0.063       | 0.085          | 0.462    | −0.106, 0.232 |
| (non-vacc = 0; vacc = 1)               | IgG1     | −0.150      | 0.113          | 0.188    | −0.375, 0.074 |
|                                        | IgG2     | −0.131      | 0.128          | 0.310    | −0.384, 0.123 |
|                                        | IgG3     | 0.028       | 0.084          | 0.743    | −0.139, 0.195 |
|                                        | IgG4     | −0.157      | 0.170          | 0.358    | −0.494, 0.180 |
| Tdap maternal vaccination timing        | Total    | 0.034       | 0.018          | 0.063    | −0.002, 0.069 |
| (gestational weeks)                    | IgG1     | 0.076       | 0.021          | 0.001    | 0.034, 0.118  |
|                                        | IgG2     | 0.071       | 0.025          | 0.007    | 0.020, 0.122  |
|                                        | IgG3     | 0.043       | 0.015          | 0.006    | 0.013, 0.073  |
|                                        | IgG4     | 0.112       | 0.038          | 0.004    | 0.007, 0.187  |

(Continued)
TABLE 4 | Continued

| Variable | Antibody | Coefficient | Standard error | p-value | 95% CI |
|----------|----------|-------------|----------------|---------|--------|
| Flu maternal vaccination status | Total | −0.039 | 0.083 | 0.640 | −0.204, 0.126 |
| (non-vacc = 0; vacc = 1) | IgG1 | −0.156 | 0.110 | 0.154 | −0.377, 0.060 |
| | IgG2 | 0.057 | 0.125 | 0.650 | −0.191, 0.305 |
| | IgG3 | −0.002 | 0.082 | 0.985 | −0.165, 0.161 |
| | IgG4 | 0.192 | 0.165 | 0.247 | −0.135, 0.519 |
| Flu maternal vaccination timing | Total | −0.009 | 0.008 | 0.270 | −0.024, 0.007 |
| (gestational weeks) | IgG1 | −0.005 | 0.011 | 0.619 | −0.027, 0.017 |
| | IgG2 | −0.018 | 0.010 | 0.076 | −0.039, 0.002 |
| | IgG3 | −0.017 | 0.006 | 0.013 | 0.013, 0.013 |
| | IgG4 | −0.002 | 0.007 | 0.750 | −0.016, 0.012 |

Bold values indicate p value < 0.05.

FIGURE 6 | Correlation between gestation at Tdap vaccination and placental transfer of total IgG and IgG subclasses. (A) Correlation between the gestation that pregnant women received the Tdap vaccine and the maternal to fetal IgG transfer ratio for total IgG and IgG subclasses [log(2) Y-axis]. Analysis was performed on log-transformed ratios by Spearman’s rank correlation coefficient, and resultant p values are stated in the bottom right corner of each plot. Coefficients: Total IgG: 0.242, IgG1: 0.316, IgG2: 0.171, IgG3: 0.353, and IgG4: 0.316. (B) Correlation between the gestation at vaccination and the antibody concentration in maternal blood and cord blood at birth. Analysis performed on log-transformed data by Spearman’s rank correlation coefficient. All correlations non-significant at p > 0.05 level. Lines indicate simple linear regression. Coefficients for maternal IgG: Total IgG: −0.044; p = 0.752, IgG1: −0.145; p = 0.262, IgG2: −0.180; p = 0.161, IgG3: 0.013; p = 0.919, IgG4: 0.029; p = 0.823. Coefficients for cord IgG: Total IgG: 0.235; p = 0.079, IgG1: 0.197; p = 0.125, IgG2: 0.134; p = 0.296, IgG3: 0.164; p = 0.199, and IgG4: 0.191; p = 0.133. N = 63.

Subclasses, neither of which were associated with birth centiles. The reason for this is unclear, but it could be an effect of higher hemodilution of IgG in a larger fetal circulation. It would be difficult to explore this; perhaps an analysis that incorporated both infant birth centiles and placental weight could shed light on this observation. Unfortunately, we did not record placental size nor weight in this current study.

Babies born to rhesus negative mothers had significantly lower levels of IgG2. These mothers were given injections of anti-D IgG at 28 weeks gestation. There appeared to be no difference in maternal levels of IgG at birth, but there were significantly lower transfer ratios of IgG2 (but not of any other subclass). This suggests that the administered IgG could compete with transfer of endogenous IgG2, but a much larger cohort of rhesus negative pregnancies is required to study this further. There may be a benefit to ensuring a time interval between maternal vaccination and anti-D infusion, if IgG2 is important for protection, and maternal vaccination studies should include Rhesus status in their analyses.

Some maternal factors were associated with changes in maternal IgG levels and the maternal/cord transfer ratio, but had no effect on final IgG levels in the neonate. Non-white
women had higher levels of IgG2 and IgG3, but the transfer ratios were lower in these pregnancies and thus cord levels were not significantly different. Older mothers had lower total IgG levels, but there was no effect on transfer nor cord levels. Interestingly, women who had previously had a live birth had higher levels of total IgG and IgG1 at birth. However, this was not reflected in neonatal blood, and the transfer ratio between maternal and cord blood was reduced in these pregnancies. Thus, as previously discussed, although maternal and cord IgG levels are positively correlated, the ability of the placenta to transfer IgG may be limited by potential saturation of Fc transport receptors at higher IgG concentrations. Previous studies found no effect of parity on the transfer of antigen-specific IgG in placental malaria nor HIV infection (36, 38), nor on cord blood antigen-specific antibody concentrations (39). The only other subclass transfer study relating to malaria and hypergammaglobulinemia also reported no effect of parity (17).

Finally, we investigated the impact of maternal vaccination on the transfer of IgG subclasses. Tdap vaccination status had no impact on maternal nor cord IgG concentrations. However, there was a positive correlation between later gestation at Tdap vaccination and higher transfer ratios of all four subclasses. This finding is of interest given that the recommended gestation for maternal Tdap/IPV vaccination has undergone several changes in the UK, partly as a result of studies showing that earlier vaccination results in higher anti-Tdap antibodies in infants. For example, a study by Eberhardt et al. (40) propose that the best cord blood levels of anti-Tdap antibodies occur when the vaccine is given between 26 and 29 weeks. However, despite this observation, the timing of Tdap/IPV was not associated with any significant changes in total/subclass IgG levels in cord blood, suggesting limited impact on bulk concentrations of IgG in the neonate. Perhaps more intriguing is our observation that babies born to influenza vaccinated mothers have significantly higher levels of IgG4. Vaccinated mothers also have higher IgG4 levels, which is interesting given that pregnancy has been previously associated with an elevated IgG4 response to seasonal influenza vaccine (41). We have previously shown that timing of influenza vaccination impacts on anti-influenza levels in babies, with the highest levels if mothers were vaccinated 4–24 weeks before delivery (42), but here we find no effect of influenza vaccine timing on neonatal levels nor transfer of the IgG subclasses.

In summary, the current study provides a detailed analysis and update on the transplacental transfer of IgG subclasses, including a review of 17 previous studies investigating maternal to fetal transfer of IgG subclasses. Most studies agree that IgG1 is the most efficiently transferred antibody subclass, with lower transfer of IgG2–4. We conclude that transfer of the IgG2–4 subclasses varies widely between study populations, but that IgG2 transfer may not be as poor as often stated. The diverse findings between studies could be due to differences in ethnicity, parity, vaccination status (including gestation of vaccination), gestation at delivery (even within term delivery populations) and birth centiles between study populations; clinical parameters that were associated with transfer ratios of total IgG and IgG subclasses from mother to fetus in our study. It is important that we continue to offer maternal vaccination to all women. Parous women, and those of non-white ethnicities may have reduced antibody transfer, and it may therefore be particularly important to engage with these demographic groups; we have previously reported maternal Tdap vaccination rates in our setting to be 36% lower in black women compared to white women (43). Encouragingly, neonatal levels of total IgG and IgG subclasses seems largely unaffected by maternal factors. However, administration of anti-D may result in lower IgG2 levels in the neonate, and maternal flu vaccination may result in higher levels of IgG4. Therefore, the impact of both of these interventions on the neonatal immune response should continue to be explored.
DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/Supplementary Material.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by London-Hampstead and Yorkshire and the Humber Research Ethics Committees. Written informed consent to participate in this study was provided by all participants.

AUTHOR CONTRIBUTIONS

BD and SB contributed to patient recruitment and collection of clinical data. TC, TR, and MB processed the samples, carried out the laboratory investigations, and contributed to data preparation. GV performed the statistical analysis and contributed to figure and table preparation. BK and CJ contributed to study design and execution. BH conceived and designed the overall study and drafted the manuscript. All authors contributed to the drafting and revision of the manuscript.

FUNDING

This paper is independent research funded by the National Institute for Health Research (NIHR) Imperial Biomedical Research Center (BRC). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health. This work was also supported by the IMMunizing PReginant women and INFants network (IMPRINT) funded by the GCRF Networks in Vaccines Research and Development, which was co-funded by the MRC and BBSRC (MR/R005990/1).

ACKNOWLEDGMENTS

We thank Anna Bosanquet and Marielle Bouqueau for their work in consenting women and their babies and Safiyah Ismail for her work optimizing the FcRn western blot. We also thank all the families who took part in this study by donating blood and placentas to research.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.01920/full#supplementary-material

Supplemental Figure 1 | Correlation between timing of maternal blood draw and maternal concentrations of total IgG and IgG subclasses profiles. Concentration of total IgG and IgG subclasses in women plotted against the timing of their blood draw. Women were bled 1 day before delivery (n = 7), on the day of delivery (n = 78), within ½ day of delivery (n = 2), within 1 day (n = 20), 2 days (n = 5) or 3 days (n = 3). Lines indicate simple linear regression (all non-significant at p > 0.05).

Supplemental Table 1 | Descriptive statistics of maternal to fetal transfer of total IgG and IgG subclasses.
hypergammaglobulinemia on transplacental transfer of antibodies and IgG subclasses in a Rural West African population. J Infect Dis. (2001) 184:627–32. doi: 10.1086/328082

18. Okoko BJ, Wesumperuma HL, Fern J, Yamuah LK, Hart CA. The transplacental transfer of IgG subclasses: influence of prematurity and low birthweight in the Gambian population. Ann Trop Paediatri. (2002) 22:325–32. doi: 10.1080/027249302125001985

19. Pitcher-Wilmott RW, Hindocha P, Wood CB. The placent al transfer of IgG subclasses in human pregnancy. Clin Exp Immunol. (1980) 41:303–8.

20. Schur PH, Alpert E, Alper C. Gamma G subgroups in human fetal, cord, and maternal sera. Clin Immunol Immunopathol. (1973) 2:62–6. doi: 10.1016/0090-1229(73)90036-6

21. Virella G, Silveira Nunes MA, Tamagnini G. Placental transfer of human IgG subclasses. Clin Exp Immunol. (1972) 10:475–8.

22. Black CM, Pilkaitys BD, Wells TW, Ramirez RM, Carlone GM, Chilmonczyk BA, et al. Two-site immunoenzymometric assays for serum IgG subclass infant/maternal ratios at full-term. J Immunol Methods. (1988) 106:71–81. doi: 10.1016/0022-1759(88)90273-6

23. De Souza EG, Hara CCP, Fagundes DLG, De Queiroz AA, Morceli G, Calderon IMP, et al. Maternal-Foetal Diabetes Modifies Neonatal Fc Receptor Expression on Human Leucocytes. Scand J Immunol. (2016) 84:237–44. doi: 10.1111/sjij.12466

24. Einarsdottir HK, Stapleton NM, Scherjon S, Andersen JT, Rispen T, van der Schoot CE, et al. On the perplexingly low rate of transport of IgG2 across the human placenta. PLoS One. (2014) 9:e108319. doi: 10.1371/journal.pone.0108319

25. Gasparoni A, Avanzini A, Ravagni Probizer F, Chirico G, Rondini G, Severi F. Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns. Am J Reprod Immunol. (2018) 80:1–7. doi: 10.1111/aji.12972

26. Lostal Gracia MI, Larrad Mur L, Pérez González JM. [IgG subclasses: placental transfer in the full-term neonate and their evolution during the first 3 months of life]. An Esp Pediatr. (1993) 38:503–8.

27. Hashira S, Okitsu-Negishi S, Yoshino K. Placental transfer of IgG subclasses in a Japanese population. Pediatr Int. (2000) 42:337–42. doi: 10.1046/j.1442-200x.2000.01245.x

28. Hay FC, Hull MGR, Torrigiani G. The transfer of human IgG subclasses from mother to foetus. (1971) 9:355–8.

29. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofoetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. (1996) 36:248–55. doi: 10.1111/j.1600-0897.1996.tb00172.x

30. Lin FC, Weisman LE, Azimi PH, Philips JB III, Clark P, Regan J, et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis. (2004) 190:928–34. doi: 10.1086/422736

31. Silveira Lessa AL, Krebs VLI, Brasil TB, Pontes GN, Carneiro-Sampaio M, Palmeira P. Preterm and term neonates transplacentally acquire IgG antibodies specific to LPS from Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa. FEMS Immunol Med Microbiol. (2011) 62:236–43. doi: 10.1111/j.1574-695X.2011.00807.x

32. Stach SCL, de Lourdes Brizot M, Liao AW, Francisco RPV, Palmeira P, Carneiro-Sampaio M, et al. Transplacental total IgG transfer in twin pregnancies. Am J Reprod Immunol. (2014) 72:555–60. doi: 10.1111/aji.12305

33. Lanoix D, St-Pierre J, Lacasse AA, Viau M, Lafond J, Vaillancourt C. Stability of reference proteins in human placenta: general protein stains are the benchmark. Placenta. (2012) 33:151–6. doi: 10.1016/j.placenta.2011.12.008

34. Harter HK, Oyede OI, Dietz K, Kreis S, Hoffman JP, Muller CP. Placental transfer and decay of maternally acquired antimeasles antibodies in Nigerian children. Pediatr Infect Dis J. (2000) 19:635–41. doi: 10.1097/00006454-200007000-00010

35. Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs. (2015) 7:331–43. doi: 10.1080/19420862.2015.1008353

36. Isabel de Moraes-Pinto M, Almeida ACM, Kenj G, Filgueiras TE, Tobias W, Santos AMN, et al. Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection. J Infect Dis. (1996) 173:1077–84. doi: 10.1093/infdis/173.5.1077

37. Lozano NA, Lozano A, Marini V, Saranz RJ, Blumberg BS, Baker K, et al. Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns. J Immunol. (2018) 199:629–36. doi: 10.1089/jimmunol.2018.00270

38. Schlaudecker E, Way S, Finkelman F. Pregnancy increases the IgG4 and decreases the IgG1 response to influenza vaccine (VAC2P.935). J Immunol. (2014) 192.

39. Doroudchi M, Samsami Dehaghani A, Emad K, Ghaderi A. Placental transfer of rubella-specific IgG in fullterm and preterm newborns. Int J Gynecol Obstet. (2003) 81:157–62. doi: 10.1016/S0020-7292(02)00442-3

40. Eberhardt CS, Blanchard-Rohner G, Lemaitre B, Boukrid M, Combesure C, Othenin-Girard V, et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis. (2016) 62:829–36. doi: 10.1093/cid/ciw027

41. Zhong Z, Haltalli M, Holder B, Rice T, Donaldson B, O’Driscoll M, et al. Maternal-Foetal Diabetes Modifies Neonatal Fc Receptor Infant/maternal ratios at full-term. Vaccine. (2019) 39:106. doi: 10.1016/j.vaccine.2019.09.055

42. Brair M-E, Brabin B, Milligan P, Maxwell S, Hart CA. Reduced transfer of tetanus antibodies with placental malaria. Lancet. (1994) 343:208–9. doi: 10.1016/S0140-6736(94)90991-1

43. Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs. (2015) 7:331–43. doi: 10.1080/19420862.2015.1008353

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Clements, Rice, Vamvakas, Barnett, Barnes, Donaldson, Jones, Kampmann and Holder. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.